首页> 美国卫生研究院文献>Journal of Clinical Oncology >Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy

【2h】

Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy

机译：DNA错配修复不足对基于FOLFOX的辅助化疗的随机试验对III期结肠癌患者的预后影响

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeThe association of deficient DNA mismatch repair (dMMR) with prognosis in patients with colon cancer treated with adjuvant fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy remains unknown.

机译：目的辅助氟尿嘧啶，亚叶酸和奥沙利铂（FOLFOX）化疗治疗的结肠癌患者中，DNA错配修复（dMMR）不足与预后的相关性尚不清楚。

著录项

期刊名称 Journal of Clinical Oncology
作者
Frank A. Sinicrope; Michelle R. Mahoney; Thomas C. Smyrk; Stephen N. Thibodeau; Robert S. Warren; Monica M. Bertagnolli; Garth D. Nelson; Richard M. Goldberg; Daniel J. Sargent; Steven R. Alberts;
展开▼
作者单位

展开▼
年(卷),期 -1(31),29
年度 -1
页码 3664–3672
总页数 10
原文格式 PDF
正文语种
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy. [J] . Frank A Sinicrope, Michelle R Mahoney, Thomas C Smyrk, Journal of Clinical Oncology . 2013 ,第29期

机译：从基于FOLFOX的辅助化疗的随机试验中，DNA错配修复不足对III期结肠癌患者的预后影响。
2. Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy. [J] . Frank A Sinicrope, Michelle R Mahoney, Thomas C Smyrk, Journal of Clinical Oncology . 2013 ,第29期

机译：从基于Folfox基辅助化疗的随机试验患者III阶段结肠癌患者缺乏DNA错配修复的预后影响。
3. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy. [J] . Zaanan A, Flejou JF, Emile JF, Clinical cancer research: an official journal of the American Association for Cancer Research . 2011 ,第23期

机译：缺陷错配修复状态作为接受FOLFOX辅助化疗的III期结肠癌患者无病生存的预后生物标志物。
4. Adjuvant Chemotherapy Should Not Routinely Be Recommended to Patients with Stage II Colon Cancers that Manifest Microsatellite Instability [C] . Sigurdis Haraldsdottir, Richard M. Goldberg Gastrointestinal Cancers Symposium . 2014

机译：不应常规向患有阶段结肠癌的患者常规的辅助化学疗法，表明微卫星不稳定性
5. Subgroup analysis based on prognostic and predictive gene signatures for adjuvant chemotherapy in early-stage non-small-cell lung cancer patients [D] . Pluta, Dustin. 2015

机译：基于预后和预测基因特征的亚组分析用于早期非小细胞肺癌患者的辅助化疗
6. Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study [O] . David Lau, Eleftheria Kalaitzaki, David N Church, 2020

机译：POLEM试验的原理和设计：avelumab联合基于氟嘧啶的化学疗法作为III期错配修复缺陷或POLE核酸外切酶结构域突变性结肠癌的辅助治疗：III期随机研究
7. Randomized phase III trial of treatment duration for oral uracil and tegafur plus leucovorin as adjuvant chemotherapy for patients with stage IIB/III colon cancer: final results of JFMC33-0502 [O] . S. Sadahiro, T. Tsuchiya, K. Sasaki, 2015

机译：口服尿嘧啶和TEGAFUR的治疗持续时间的随机期III试验作为阶段IIB / III结肠癌患者的辅助化学疗法：JFMC33-0502的最终结果

Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy

摘要

著录项

相似文献

相关主题

期刊订阅